Ultrasound-guided radiofrequency is generally a safe treatment for liver masses and carries an acceptable level of risk, but patients with large tumors and baseline liver function impairment have a higher risk of complications, according to researchers in Taiwan.
Ultrasound-guided radiofrequency is generally a safe treatment for liver masses and carries an acceptable level of risk, but patients with large tumors and baseline liver function impairment have a higher risk of complications, according to researchers in Taiwan.
Dr. Tsung-Ming Chen and colleagues in the hepatogastroenterology division of the internal medicine department at Tungs' Taichung MetroHarbor Hospital in Taiwan published their paper online in August with the Journal of Gastroenterology and Hepatology. They studied results from all patients at a single center treated by one physician, 104 in all, with a total of 183 tumors.
The analysis included 172 ultrasound-guided percutaneous radiofrequency ablation sessions between May 2003 and March 2006 on 86 hepatocellular carcinomas and 18 hepatic metastatic tumors. They found only nine major complications as defined by the standardized Society of Interventional Radiology grading system, resulting in an incidence of 5.2% chance per session.
These nine complications included two cases of transient liver function impairment, one case of liver abscess, one case of septicemia, two cases of tumor seeding along the ablated track, one case of colon perforation, one case of acalculous cholecystitis and one case of hemocholecyst. In analyzing these cases, they found tumor size and baseline liver function reserve were the only risk factors contributing to the complication of transient liver function impairment.
The researchers concluded that patients with a large tumor size and baseline liver function impairment should be watched more carefully in follow-up.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Month, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.